ORGANIZATION

EFPIA Report Calls Japan a “Cautionary Tale” in 10-Country Biopharma Strategy Review

By Ken Yoshino March 2, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has released a comparative analysis of biopharmaceutical strategies across 10 countries, describing Japan as a “cautionary tale” where multiple policy factors have eroded the market’s international attractiveness. The report analyzes pharmaceutical…

To read the full story

Japan Ranks 9th Among 10 in AI Analysis of EFPIA Pharma Strategy Report
March 27, 2026

ORGANIZATION

Society Envisions 1 Trillion Yen in Overseas Sales for Japan’s Off-Patent Drug Sector by 2040
June 9, 2026
Employees of 9 Pharma Firms Team Up for LGBTQ+ Inclusion
June 8, 2026
Time Ripe for Debate on Drug Spending Macroeconomic Indexing: INES
June 3, 2026
Labor Group Urges MHLW to Support Pharma Talent Development
June 3, 2026
Labor Group Urges Govt to View Pharma as Investment, Not Cost
June 1, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

20 Years at a Glance: Overseas Sales Surge at Japan Pharma, but R&D Investments Lag

By Hayate Horiguchi

Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…